scholarly journals 163 Pathological assessment of lymph node status in cervical cancer: complete embedding does not does not yield more node metastases

2021 ◽  
Author(s):  
J Vaneman ◽  
RGV Smolders ◽  
PC Ewing-Graham ◽  
HJ Van Beekhuizen ◽  
HC Van Doorn
Keyword(s):  
Cervical Cancer ◽  
Lymph Node ◽  
Lymph Node Status ◽  
Node Status ◽  
Node Metastases ◽  
Pathological Assessment

The value of tumor marker and cytokine analysis for the assessment of regional lymph node status in cervical cancer patients

2008 ◽  
Vol 18 (6) ◽  
pp. 1279-1284 ◽  
Author(s):  
B. Kotowicz ◽  
M. Fuksiewicz ◽  
M. Kowalska ◽  
J. Jonska-Gmyrek ◽  
M. Bidzinski ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Lymph Node ◽  
Lymph Node Metastases ◽  
Regional Lymph Node ◽  
Serum Levels ◽  
Lymph Node Involvement ◽  
Lymph Node Status ◽  
Node Status ◽  
Node Involvement ◽  
Node Metastases

The aim of the study was to evaluate the utility of the measurements of the circulating tumor markers, squamous cell carcinoma antigen (SCCA), CA125, carcinoembryonic antigen (CEA), cytokeratin fragment 19 (CYFRA 21.1), and the cytokines, interleukin-6 and vascular endothelial growth factor (VEGF), to estimate regional lymph node involvement in patients with cervical cancer. The study comprised 182 untreated patients with cervical cancer. The regional lymph node status was assessed either by the postsurgical histopathologic examination or by the computed tomography (CT). Concentrations of SCCA, CEA, and CA125 were determined using the Abbott Instruments system, of CYFRA 21.1 by the Roche kits, and of IL-6 and VEGF by the ELISA of R&D Systems (Minneapolis, MN). For the statistical analyses, Mann–Whitney U test and χ2 test were applied. Serum levels of SCCA, CEA, CA125, CYFRA 21.1, IL-6, and VEGF were measured in patients with specified pelvic and para-aortic lymph node status. SCCA, CA125, and IL-6 levels were found to be significantly higher in patients with lymph node metastases than in those with no lymph node involvement. Also, the percentage of patients with simultaneously elevated concentrations of SCCA and CA125 or SCCA and IL-6 differed depending on the lymph node status and was significantly higher in the series of patients with lymph node metastases. Simultaneous assessment of serum levels of SCCA and CA125 or SCCA and IL-6 in patients with cervical cancer may be useful for the regional lymph node evaluation, especially in patients with advanced stages, when the lymph nodes are examined only by CT, with no histologic confirmation.

scholarly journals Risk Stratification Based on Metastatic Pelvic Lymph Node Status in Stage IIIC1p Cervical Cancer

2020 ◽  
Vol Volume 12 ◽  
pp. 6431-6439
Author(s):  
Anyang Li ◽  
Luhui Wang ◽  
Qi Jiang ◽  
Wenlie Wu ◽  
Baoyou Huang ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Lymph Node ◽  
Risk Stratification ◽  
Pelvic Lymph Node ◽  
Lymph Node Status ◽  
Node Status

Prospective evaluation of PET/CT for lymph node status in FIGO stage IB–IIA cervical cancer

2011 ◽  
Vol 120 ◽  
pp. S113
Author(s):  
K. Lee ◽  
S. Lim ◽  
S. Cheon ◽  
S. Park ◽  
C. Park
Keyword(s):  
Cervical Cancer ◽  
Lymph Node ◽  
Figo Stage ◽  
Lymph Node Status ◽  
Prospective Evaluation ◽  
Stage Ib ◽  
Node Status ◽  
Pet Ct

ATL

2012 ◽  
Vol 22 (7) ◽  
pp. 1226-1233 ◽  
Author(s):  
Jang Yoo ◽  
Joon Young Choi ◽  
Seung Hwan Moon ◽  
Duk Soo Bae ◽  
Soo Bin Park ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Prognostic Factors ◽  
Lymph Node ◽  
Fdg Pet ◽  
Tumor Volume ◽  
Metabolic Tumor Volume ◽  
Uterine Cervical Cancer ◽  
Lymph Node Status ◽  
Free Survival ◽  
Node Status

ObjectiveWe compared the prognostic value of volume-based metabolic parameters determined using fluorine 18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET) (18F-FDG PET) (with other prognostic parameters in uterine cervical cancer.MethodsThe subjects were 73 female patients who had an initial diagnosis of uterine cervical cancer and who underwent 18F-FDG PET. Various metabolic or volume-based PET parameters including maximum and average standardized uptake values, metabolic tumor volume, and total lesion glycolysis (TLG) were measured in primary cervical tumors. Survival analysis for disease-free survival or progression-free survival was performed with a Kaplan-Meier method using PET parameters and other clinical variables. For determining independent prognostic factors, Cox regression analysis was performed.ResultsRecurrence or disease progression occurred in 23 patients (31.5%). In univariate analysis, patient age (cutoff, 57 years, P < 0.05), International Federation of Gynecology and Obstetrics stage (P = 0.07), primary tumor size (cutoff, 6.7 cm; P < 0.05), lymph node status on PET (P < 0.005), treatment method (P < 0.01), metabolic tumor volume (cutoff, 82 cm3; P = 0.001), and TLG (cutoff, 7600; P = 0.005) were significant predictors of recurrence or progression. In multivariate analysis, both lymph node status on PET (hazard ratio, 1.042 [negative vs intrapelvic metastasis only], 7.008 [negative vs extrapelvic metastasis]; P < 0.001) and TLG (cutoff, 7600; hazard ratio, 2.981; P < 0.05) were independent prognostic factors for predicting recurrence.ConclusionsIn uterine cervical cancer, TLG, a volume-based metabolic parameter, and lymph node status on PET may be significant independent prognostic factors for event-free survival.

scholarly journals Circulating microRNAs in Early Breast Cancer Patients and Its Association With Lymph Node Metastases

2020 ◽  
Author(s):  
Daniel Escuin ◽  
Laura López-Vilaró ◽  
Olga Bell ◽  
Josefina Mora ◽  
Antonio Moral ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Lymph Node Status ◽  
Breast Cancer Patients ◽  
Circulating Mirnas ◽  
Node Status ◽  
Differentially Expressed Mirnas ◽  
Node Metastases

Abstract Background: In recent years, miRNAs have emerged as important regulators of many cellular processes, including the various steps of the metastatic process. In addition, circulating miRNAs appear to be surprisingly stable in peripheral blood making them ideal noninvasive biomarkers for disease diagnosis. Here, we investigated the expression profile of circulating miRNAs and their association with the metastatic lymph node status in early breast cancer patients. Methods: We designed a proof-of-principle study using 16 plasma samples from patients with known sentinel lymph node status (n=12 positive and n=4 negative). We performed RNA-sequencing and validated the results by qPCR. Gene Ontology term enrichment and KEGG pathway analyses were carried out using DAVID tools.Results: We found16 differentially expressed miRNAs after adjusting for false discovery correction (q < 0.01) in patients with positive samples. Thirteen miRNAs were down-regulated (miR-339-5p, miR-133a-3p, miR-326, miR-331-3p, miR-369-3p, miR-328-3p, miR-26a-3p, miR-139-3p, miR-493-3p, miR-664a-5p, miR-323b-3pmiR-1307-3p and miR-423-3p) and 3 were up-regulated (miR-101-3p, miR-146a-5p and miR-144-3p). Hierarchical clustering using differentially expressed miRNAs clearly distinguished patients according to their lymph node status. We did not find any difference in the miRNA expression profile between plasma samples associated with macrometastasis or micrometastasis. The expression of 9 miRNAs was validated by qPCR. Moreover, gene ontology analysis showed a significant enrichment of biological processes associated with the regulation of the epithelial mesenchymal transition, cell proliferation and transcriptional regulation. Conclusions: Our results indicated the potential role of several circulating miRNAs as surrogate markers of lymph node metastases in early breast cancer patients. Further validation in a larger cohort of patients will be necessary to confirm our results.

Sign in / Sign up

Export Citation Format

Share Document